Stocks Health care CSBR
NASDAQ · Health careChampions Oncology, Inc. (CSBR)
Champions Oncology, Inc. brought in $60.7M of revenue over the twelve months to July 31, 2026, up 6.7% from a year earlier. It posted a net loss of $1.1M. In fiscal 2026 capital spending exceeded operating cash flow by $5M. At July 31, 2026 it held $4.4M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on September 11, 2026.
Key facts about Champions Oncology, Inc.
- Net worth
- Champions Oncology, Inc. has a market value (market cap) of $66M at the latest share price, and shareholders' equity of $3.9M on its balance sheet at July 31, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2026 revenue was $59.4M (+4.4% year on year), with a net loss of $1.2M. Over the 12 months to July 31, 2026: revenue $60.7M, net loss $1.1M.
- Cash flow
- In fiscal 2026 operations used $4.5M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on September 11, 2026 and covers the period to July 31, 2026. Open on SEC EDGAR
- Next earnings report
- Champions Oncology, Inc.'s next report is expected around December 14, 2026. That is an estimate from its filing rhythm, not a date the company has announced.
What Champions Oncology, Inc. does
Champions Oncology, Inc. is registered with the SEC under industry code SIC 2836 (Biological Products, (No Diagnostic Substances)). Its shares trade on NASDAQ under the ticker CSBR.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2026 | $59.4M | -$1.2M | -$0.08 | -$5M |
| 2025 | $56.9M | $4.7M | $0.33 | $7M |
| 2024 | $50.2M | -$7.3M | -$0.54 | -$7M |
| 2023 | $53.9M | -$5.3M | -$0.39 | $1.1M |
| 2022 | $49.1M | $548K | $0.04 | $4.1M |
| 2021 | $41M | $362K | $0.02 | -$5M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where CSBR ranks in Health care
Latest SEC filings
What Champions Oncology, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- September 11, 2026Quarterly report 10-Q · period to July 31, 2026Revenue rose 8.8% to $15.2M versus the same quarter last year; diluted EPS -$0.03 versus -$0.03.
- September 10, 2026
- August 28, 2026Additional proxy material DEFA14A
- August 28, 2026Proxy statement DEF 14A
- July 27, 2026Annual report 10-K · period to April 30, 2026Revenue rose 4.4% to $59.4M versus the prior year; diluted EPS -$0.08 versus $0.33.
- July 27, 2026
- March 30, 2026
- March 12, 2026Quarterly report 10-Q · period to January 31, 2026Revenue fell 2.8% to $16.6M versus the same quarter last year; diluted EPS -$0.02 versus $0.31.
- March 12, 2026
- December 15, 2025Quarterly report 10-Q · period to October 31, 2025Revenue rose 11% to $15M versus the same quarter last year; diluted EPS $0.02 versus $0.05.
Insider trades
What the people running Champions Oncology, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider trades were reported in the last 90 days.
Who owns CSBR
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| New Enterprise Associates 14, L.P.13D, may seek influence with 7 related filers | 12.6% | May 6, 2024 |
| West Elk Partners, LP13G, passive with 4 related filers | 6.49% | November 14, 2024 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 28 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| Battery Management Corp. | 2,421,673 | 0 |
| NEA Management Company, LLC | 1,713,720 | 0 |
| Vanguard Capital Management LLC | 301,353 | +1,833 |
| Tocqueville Asset Management L.P. | 295,658 | -24,016 |
| Morgan Stanley | 235,400 | -6,900 |
| Bank of America Corp | 214,058 | +192,225 |
| Renaissance Technologies LLC | 139,039 | -6,500 |
| BlackRock, Inc. | 129,848 | +5,948 |
| Mink Brook Asset Management LLC | 111,338 | 0 |
| Geode Capital Management, LLC | 76,300 | -877 |
| HighTower Advisors, LLC | 41,901 | +6,743 |
| Vanguard Fiduciary Trust Co | 33,239 | +247 |
| Northern Trust Corp | 27,910 | -18,022 |
| State Street Corp | 26,203 | 0 |
| Bank of New York Mellon Corp | 21,614 | 0 |
| Citadel Advisors LLC | 18,295 | new |
| Essex Investment Management Co LLC | 18,221 | -28 |
| Mesirow Financial Investment Management, Inc. | 15,800 | 0 |
| Mercer Global Advisors Inc | 12,775 | new |
| Vanguard Global Advisers, LLC | 2,093 | 0 |
Insiders
Questions about CSBR
What does Champions Oncology, Inc. do?
Champions Oncology, Inc. is a company in the Health care sector, listed on NASDAQ as CSBR. Its shares trade on NASDAQ under the ticker CSBR.
What is Champions Oncology, Inc.'s net worth?
Champions Oncology, Inc. has a market value (market cap) of $66M at the latest share price, and shareholders' equity of $3.9M on its balance sheet at July 31, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Champions Oncology, Inc. profitable?
No. Over the twelve months to July 31, 2026 it reported a net loss of $1.1M on revenue of $60.7M.
How much revenue does Champions Oncology, Inc. make?
Over the twelve months to July 31, 2026 Champions Oncology, Inc. reported revenue of $60.7M. That is 6.7% more than a year earlier.
When did Champions Oncology, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on September 11, 2026. It covers the period to July 31, 2026.
When is Champions Oncology, Inc.'s next earnings report?
Champions Oncology, Inc.'s next report is expected around December 14, 2026. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare CSBR with
Follow CSBR
Get an email when Champions Oncology, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Champions Oncology, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.